Articles related to SUDDEN CARDIAC DEATH (SDC)

The recommendations from the American Academy of Pediatrics (AAP) are an update to the group’s 2012 policy statement in an effort to better equip physicians with the necessary knowledge to accurately screen, evaluate, and manage the risk of both sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in youth. Screening for all children, regardless of athletic status, should be completed at least every three years.

The action comes after observational evidence associating the HeartWare left ventricular assist device (LVAD) with increased neurological adverse events and mortality, as well as more than 100 complaints involving delay or failure to restart. First approved in November 2012, the LVAD has been implanted in approximately 2,000 US patients experiencing end-stage heart failure.

The FDA announced a trial hold after two participants with sickle cell disease (SCD) in the LentiGlobin gene therapy trials developed AML and MDS. According to bluebird bio, the manufacturer of LentiGlobin products, the company was unable to find any cancer cells in the patient’s bone marrow and has asked the FDA for permission to resume clinical trials.